Medical Access and Reimbursement in Jordan

Currently classified as a strictly controlled substance under Jordanian drug and psychotropic‑substance law, with no authorized medical use outside of approved clinical research. National legislation adopted and strengthened around 2015–2016 treats trafficking, possession and manufacture of psychotropic substances as criminal offences, and the public reporting and enforcement posture indicates no regulatory pathway for medical prescription or public reimbursement for psilocybin. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Jordanian enforcement and statutory frameworks do not provide for routine medical/therapeutic prescribing or reimbursement for MDMA‑assisted therapy. #

Esketamine (Spravato) has no public record of a Jordanian marketing authorisation or inclusion on Jordanian public reimbursement lists; there is no evidence of Janssen’s Spravato programme (or a local registration) being available or reimbursed in Jordan. Esketamine as a licensed, supervised psychiatric product is distributed only in jurisdictions where a company filing and national regulator approval exist; absence of a public approval record and Jordan’s restrictive national psychotropic laws mean esketamine is not available as a reimbursed treatment in routine care in Jordan. For context: Janssen has announced approvals in multiple countries but does not list Jordan among publicly reported marketing authorisations. # #

Ketamine is an established anaesthetic and analgesic that is used within Jordanian hospital settings for surgical and emergency indications; local clinical activity (including investigator‑led trials and perioperative use) demonstrates medically‑supervised use of ketamine within Jordan’s public and military hospitals. For example, a Jordanian Royal Medical Services clinical trial record documents intramuscular ketamine use in a postoperative study, indicating institutional medical use of ketamine for anaesthesia/analgesia in Jordan. #

However, ketamine for psychiatric indications (e.g., sub‑anaesthetic infusion for treatment‑resistant depression) is not an approved, reimbursed psychiatric treatment in Jordan. There is no published Jordanian national reimbursement policy or Ministry of Health guidance endorsing ketamine infusions for depression or providing public insurance coverage for off‑label ketamine psychotherapy; any such psychiatric use would be off‑label, institutionally governed, and at patients’ private expense where it occurs. Jordan’s drug control law and enforcement practices mean diversion and non‑medical possession are criminally sanctioned, so outpatient or unsupervised psychedelic/abusive forms of ketamine use are strictly regulated. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no recognized clinical or reimbursement pathway for DMT in Jordan. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No medical reimbursement or authorised therapeutic programmes exist for 5‑MeO‑DMT in Jordan. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Jordan has no regulatory pathway or public reimbursement for ibogaine‑based addiction treatments. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Plant mixtures containing DMT (such as ayahuasca) fall under the same controlled‑substance prohibitions in Jordan and are not covered by any medical reimbursement system. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no legal medical/therapeutic pathway or reimbursement for mescaline in Jordan. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Jordanian statutes and enforcement treat novel phenethylamine derivatives as illicit; there is no medical access or reimbursement for 2C‑X compounds. #